X4 Pharmaceuticals Stock Performance
| XFOR Stock | USD 4.00 0.02 0.50% |
On a scale of 0 to 100, X4 Pharmaceuticals holds a performance score of 5. The firm owns a Beta (Systematic Risk) of 1.57, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, X4 Pharmaceuticals will likely underperform. Please check X4 Pharmaceuticals' potential upside, and the relationship between the jensen alpha and accumulation distribution , to make a quick decision on whether X4 Pharmaceuticals' current price history will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in X4 Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Even with relatively uncertain basic indicators, X4 Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.5 | Five Day Return 10.5 | Year To Date Return 2.83 | Ten Year Return (99.84) | All Time Return (99.84) |
Last Split Factor 1:30 | Dividend Date 2019-03-14 | Last Split Date 2025-04-28 |
1 | Disposition of 49678 shares by Paula Ragan of X4 Pharmaceuticals at 0.8828 subject to Rule 16b-3 | 11/11/2025 |
2 | Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing - Yahoo Finance | 11/24/2025 |
3 | X4 Pharmaceuticals Betting On Mavorixafor For Chronic Neutropenia - Seeking Alpha | 12/01/2025 |
4 | X4 Pharmaceuticals, Inc.s Shares May Have Run Too Fast Too Soon | 12/24/2025 |
5 | Acquisition by Bridger Gary of 110000 shares of X4 Pharmaceuticals at 4.0 subject to Rule 16b-3 | 01/07/2026 |
6 | X4 Pharmaceuticals, Inc. Receives 34.50 Consensus Target Price from Brokerages | 01/13/2026 |
7 | X4 Pharmaceuticals to Participate in Guggenheims Emerging Outlook Biotech Summit 2026 | 02/03/2026 |
| Begin Period Cash Flow | 100.2 M | |
| Total Cashflows From Investing Activities | 67 M |
X4 Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 351.00 in X4 Pharmaceuticals on November 6, 2025 and sell it today you would earn a total of 49.00 from holding X4 Pharmaceuticals or generate 13.96% return on investment over 90 days. X4 Pharmaceuticals is currently generating 0.32% in daily expected returns and assumes 4.6152% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than XFOR, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
X4 Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of XFOR Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.00 | 90 days | 4.00 | about 19.08 |
Based on a normal probability distribution, the odds of X4 Pharmaceuticals to move above the current price in 90 days from now is about 19.08 (This X4 Pharmaceuticals probability density function shows the probability of XFOR Stock to fall within a particular range of prices over 90 days) .
X4 Pharmaceuticals Price Density |
| Price |
Predictive Modules for X4 Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as X4 Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.X4 Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. X4 Pharmaceuticals is not an exception. The market had few large corrections towards the X4 Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold X4 Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of X4 Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.13 | |
β | Beta against Dow Jones | 1.57 | |
σ | Overall volatility | 0.24 | |
Ir | Information ratio | 0.03 |
X4 Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of X4 Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for X4 Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| X4 Pharmaceuticals had very high historical volatility over the last 90 days | |
| X4 Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (37.45 M) with profit before overhead, payroll, taxes, and interest of 28.28 M. | |
| X4 Pharmaceuticals currently holds about 47.38 M in cash with (130.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69. | |
| Latest headline from finance.yahoo.com: X4 Pharmaceuticals to Participate in Guggenheims Emerging Outlook Biotech Summit 2026 |
X4 Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of XFOR Stock often depends not only on the future outlook of the current and potential X4 Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. X4 Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.7 M | |
| Cash And Short Term Investments | 102.1 M |
X4 Pharmaceuticals Fundamentals Growth
XFOR Stock prices reflect investors' perceptions of the future prospects and financial health of X4 Pharmaceuticals, and X4 Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XFOR Stock performance.
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (2.80) % | ||||
| Operating Margin | (12.81) % | ||||
| Current Valuation | 303.16 M | ||||
| Shares Outstanding | 87.44 M | ||||
| Price To Book | 5.67 X | ||||
| Price To Sales | 10.29 X | ||||
| Revenue | 2.56 M | ||||
| Gross Profit | 28.28 M | ||||
| EBITDA | (27.58 M) | ||||
| Net Income | (37.45 M) | ||||
| Cash And Equivalents | 47.38 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 78.09 M | ||||
| Debt To Equity | 1.28 % | ||||
| Current Ratio | 2.39 X | ||||
| Book Value Per Share | 2.45 X | ||||
| Cash Flow From Operations | (130.9 M) | ||||
| Earnings Per Share | (8.92) X | ||||
| Market Capitalization | 349.75 M | ||||
| Total Asset | 146.45 M | ||||
| Retained Earnings | (515.36 M) | ||||
| Working Capital | 79.3 M | ||||
About X4 Pharmaceuticals Performance
Assessing X4 Pharmaceuticals' fundamental ratios provides investors with valuable insights into X4 Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the X4 Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.5 K | 1.3 K | |
| Return On Tangible Assets | (0.28) | (0.30) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (1.94) | (2.04) |
Things to note about X4 Pharmaceuticals performance evaluation
Checking the ongoing alerts about X4 Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for X4 Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| X4 Pharmaceuticals had very high historical volatility over the last 90 days | |
| X4 Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (37.45 M) with profit before overhead, payroll, taxes, and interest of 28.28 M. | |
| X4 Pharmaceuticals currently holds about 47.38 M in cash with (130.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69. | |
| Latest headline from finance.yahoo.com: X4 Pharmaceuticals to Participate in Guggenheims Emerging Outlook Biotech Summit 2026 |
- Analyzing X4 Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether X4 Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining X4 Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating X4 Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of X4 Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of X4 Pharmaceuticals' stock. These opinions can provide insight into X4 Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.